Jazz Pharmaceuticals (NASDAQ:JAZZ) Reaches New 1-Year High – Should You Buy?

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) hit a new 52-week high during trading on Monday . The company traded as high as $257.00 and last traded at $255.89, with a volume of 174866 shares trading hands. The stock had previously closed at $253.87.

Analyst Ratings Changes

Several research firms recently weighed in on JAZZ. Canaccord Genuity Group assumed coverage on shares of Jazz Pharmaceuticals in a report on Thursday, July 16th. They set a “buy” rating and a $290.00 target price on the stock. Bank of America raised their price objective on Jazz Pharmaceuticals from $281.00 to $307.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. UBS Group upgraded Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $188.00 to $307.00 in a research note on Tuesday, May 19th. Wells Fargo & Company upped their target price on Jazz Pharmaceuticals from $265.00 to $285.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 14th. Finally, Truist Financial lowered their target price on Jazz Pharmaceuticals from $256.00 to $254.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $259.06.

Jazz Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85. The firm has a market cap of $16.07 billion, a price-to-earnings ratio of -12,783.61, a P/E/G ratio of 0.22 and a beta of 0.32. The business’s 50-day moving average price is $237.37 and its two-hundred day moving average price is $203.44.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. The business had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. On average, research analysts forecast that Jazz Pharmaceuticals PLC will post 21.9 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Heather Ann Mcsharry sold 2,000 shares of the stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $241.00, for a total transaction of $482,000.00. Following the transaction, the director owned 18,449 shares of the company’s stock, valued at approximately $4,446,209. This trade represents a 9.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Neena M. Patil sold 1,200 shares of Jazz Pharmaceuticals stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total value of $278,196.00. Following the completion of the transaction, the executive vice president owned 51,549 shares of the company’s stock, valued at $11,950,604.67. This trade represents a 2.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 13,098 shares of company stock worth $3,131,906. 4.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of JAZZ. Arista Wealth Management LLC bought a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter valued at approximately $241,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in Jazz Pharmaceuticals during the second quarter worth $61,000. GAMMA Investing LLC boosted its holdings in Jazz Pharmaceuticals by 18.8% in the second quarter. GAMMA Investing LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock worth $339,000 after purchasing an additional 223 shares during the period. Harbor Investment Advisory LLC boosted its holdings in Jazz Pharmaceuticals by 349.2% in the second quarter. Harbor Investment Advisory LLC now owns 292 shares of the specialty pharmaceutical company’s stock worth $70,000 after purchasing an additional 227 shares during the period. Finally, Versant Capital Management Inc increased its stake in Jazz Pharmaceuticals by 14.9% during the second quarter. Versant Capital Management Inc now owns 2,357 shares of the specialty pharmaceutical company’s stock valued at $568,000 after purchasing an additional 305 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.